Loss of Suppressors of Cytokine Signaling 3 Promotes Aggressiveness in Hepatocellular Carcinoma

REFERENCES

• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264–1273, e1261.
   PubMed Web of Science ®Google Scholar
• He J, Gu D, Wu X, Major causes of death among men and women in China. N Engl J Med. 2005;353:1124–1134.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Tsao L, Hsing AW, International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290–296.
   PubMed Web of Science ®Google Scholar
• Wu ZS, Cheng XW, Wang XN, Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in human cutaneous melanoma. Melanoma Res. 2011;21:483–490.
   PubMedGoogle Scholar
• Wu WY, Li J, Wu ZS, Prognostic significance of phosphorylated signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 expression in hepatocellular carcinoma. Exp Ther Med. 2011;2:647–653.
   PubMedGoogle Scholar
• Wang Z, Zhu S, Shen M, STAT3 is involved in esophageal carcinogenesis through regulation of Oct-1. Carcinogenesis 2013;34:678–688.
   PubMed Web of Science ®Google Scholar
• Bowman T, Garcia R, Turkson J, STATs in oncogenesis. Oncogene 2000;19:2474–2488.
   PubMed Web of Science ®Google Scholar
• Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293–322.
   PubMed Web of Science ®Google Scholar
• O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–170.
   PubMed Web of Science ®Google Scholar
• Calo V, Migliavacca M, Bazan V, STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol. 2003;197:157–168.
   PubMed Web of Science ®Google Scholar
• Gao B, Wang H, Lafdil F, STAT proteins –key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver. J Hepatol. 2012;57:430–441.
   PubMed Web of Science ®Google Scholar
• Wu WY, Li J, Wu ZS, STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506.
   PubMed Web of Science ®Google Scholar
• Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503–529.
   PubMed Web of Science ®Google Scholar
• Baltayiannis G, Baltayiannis N, Tsianos EV. Suppressors of cytokine signaling as tumor repressors. Silencing of SOCS3 facilitates tumor formation and growth in lung and liver. J BUON. 2008;13:263–265.
   PubMed Web of Science ®Google Scholar
• Huang WT, Yang SF, Wu CC, Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci. 2009;25:640–646.
   PubMedGoogle Scholar
• Ying M, Li D, Yang L, Loss of SOCS3 expression is associated with an increased risk of recurrent disease in breast carcinoma. J Cancer Res Clin Oncol. 2010;136:1617–1626.
   PubMedGoogle Scholar
• Wu ZS, Wang CQ, Xiang R, Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 2012;12:51.
   PubMedGoogle Scholar
• Song S, Lippman SM, Zou Y, Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene 2005;24:8268–8276.
   PubMedGoogle Scholar
• Fan Y, Boivin GP, Knudsen ES, The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010;70:212–220.
   PubMed Web of Science ®Google Scholar
• Vesselinovitch SD, Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 1983;43:4253–4259.
   PubMed Web of Science ®Google Scholar
• Choi JH, Ahn MJ, Park CK, Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray. APMIS 2006;114:619–625.
   PubMed Web of Science ®Google Scholar
• Hoikkala S, Paakko P, Soini Y, Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2–complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma. Cancer Lett. 2006;236:125–132.
   PubMed Web of Science ®Google Scholar
• Flikkema RM, Toledo AH, Anaya-Prado R, Principles of statistics in surgery. J Invest Surg. 2011;24:237–242.
   PubMed Web of Science ®Google Scholar
• Leber MF, Efferth T. Molecular principles of cancer invasion and metastasis (review). Int J Oncol. 2009;34:881–895.
   PubMed Web of Science ®Google Scholar
• Li L, Gao Y, Zhang LL, Concomitant activation of the JAK/STAT3 and ERK1/2 signaling is involved in leptin-mediated proliferation of renal cell carcinoma Caki-2 cells. Cancer Biol Ther. 2008;7:1787–1792.
   PubMed Web of Science ®Google Scholar
• Yu LF, Cheng Y, Qiao MM, Activation of STAT3 signaling in human stomach adenocarcinoma drug-resistant cell line and its relationship with expression of vascular endothelial growth factor. World J Gastroenterol. 2005;11:875–879.
   PubMed Web of Science ®Google Scholar
• Kusaba T, Nakayama T, Yamazumi K, Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 2005;58:833–838.
   PubMed Web of Science ®Google Scholar
• Sriuranpong V, Park JI, Amornphimoltham P, Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63:2948–2956.
   PubMed Web of Science ®Google Scholar
• Niu G, Bowman T, Huang M, Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001–7010.
   PubMed Web of Science ®Google Scholar
• Mora LB, Buettner R, Seigne J, Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62:6659–6666.
   PubMed Web of Science ®Google Scholar
• Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140–3148.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Nowak I, Vonderheid EC, Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc Natl Acad Sci USA 1996;93:9148–9153.
   PubMed Web of Science ®Google Scholar
• Weber-Nordt RM, Egen C, Wehinger J, Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996;88:809–816.
   PubMed Web of Science ®Google Scholar
• Sanchez A, Nagy P, Thorgeirsson SS. STAT-3 activity in chemically induced hepatocellular carcinoma. Eur J Cancer. 2003;39:2093–2098.
   PubMedGoogle Scholar
• Calvisi DF, Ladu S, Gorden A, Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 2006;130:1117–1128.
   PubMed Web of Science ®Google Scholar
• Bromberg JF, Wrzeszczynska MH, Devgan G, Stat3 as an oncogene. Cell 1999;98:295–303.
   PubMed Web of Science ®Google Scholar
• Yang SF, Yeh YT, Wang SN, SOCS-3 is associated with vascular invasion and overall survival in hepatocellular carcinoma. Pathology 2008;40:558–563.
   PubMed Web of Science ®Google Scholar
• Bard-Chapeau EA, Li S, Ding J, Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 2011;19:629–639.
   PubMed Web of Science ®Google Scholar
• Basu A, Meyer K, Lai KK, Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology 2006;349:347–358.
   PubMed Web of Science ®Google Scholar
• Christodoulidis G, Tsilioni I, Spyridakis ME, Matrix metaloproteinase-2 and -9 serum levels as potential markers of intraperitoneal adhesions. J Invest Surg. 2013;26:134–140.
   PubMed Web of Science ®Google Scholar
• Gullu IH, Kurdoglu M, Akalin I. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. Br J Cancer. 2000;82:249.
   PubMedGoogle Scholar
• Chen R, Cui J, Xu C, The significance of MMP-9 over MMP-2 in HCC invasiveness and recurrence of hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2012;19(Suppl 3):S375–S384.
   PubMedGoogle Scholar
• Wu X, Yan Q, Zhang Z, Acrp30 inhibits leptin-induced metastasis by downregulating the JAK/STAT3 pathway via AMPK activation in aggressive SPEC-2 endometrial cancer cells. Oncol Rep. 2012;27:1488–1496.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Uemura H, Nagahama K, Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012;3:1455–1471.
   PubMedGoogle Scholar
• Syed ZA, Yin W, Hughes K, HGF/c-met/Stat3 signaling during skin tumor cell invasion: indications for a positive feedback loop. BMC Cancer 2011;11:180.
   PubMed Web of Science ®Google Scholar
• Senft C, Priester M, Polacin M, Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol. 2011;101:393–403.
   Google Scholar
• Hsu CP, Chen YL, Huang CC, Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest. 2011;41:277– 284.
   PubMed Web of Science ®Google Scholar
• Landen CN, Jr., Lin YG, Armaiz Pena GN, Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer. Cancer Res. 2007;67:10389–10396.
   PubMed Web of Science ®Google Scholar